Why PTC Therapeutics, Inc.'s (NASDAQ:PTCT) CEO Pay Matters To YouHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Why PTC Therapeutics, Inc.'s (NASDAQ:PTCT) CEO Pay Matters To YouSimply Wall StSimply Wall St.January 7, 2020ReblogShareTweetShareView photosIn 1998 Stuart Peltz was appointed CEO of PTC Therapeutics, Inc. (NASDAQ:PTCT). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Then we'll look at a snap shot of the business growth. Third, we'll reflect on the total return to shareholders over three years, as a second measure of business performance. This method should give us information to assess how appropriately the company pays the CEO. View our latest analysis for Therapeutics How Does Stuart Peltz's Compensation Compare With Similar Sized Companies?At the time of writing, our data says that PTC Therapeutics, Inc. has a market cap of US$3.1b, and reported total annual CEO compensation of US$4.0m for the year to December 2018. While we always look at total compensation first, we note that the salary component is less, at US$659k. We further remind readers that the CEO may face performance requirements to receive the non-salary part of the total compensation. As part of our analysis we looked at companies in the same jurisdiction, with market capitalizations of US$2.0b to US$6.4b. The median total CEO compensation was US$5.1m.That means Stuart Peltz receives fairly typical remuneration for the CEO of a company that size. Although this fact alone doesn't tell us a great deal, it becomes more relevant when considered against the business performance.The graphic below shows how CEO compensation at Therapeutics has changed from year to year.NasdaqGS:PTCT CEO Compensation, January 7th 2020MoreIs PTC Therapeutics, Inc. Growing?On average over the last three years, PTC Therapeutics, Inc. has grown earnings per share (EPS) by 7.4% each year (using a line of best fit). In the last year, its revenue is up 16%.This revenue growth could really point to a brighter future. And the improvement in earnings per share is modest but respectable. So while we'd stop just short of calling this a top performer, but we think it is well worth watching. Shareholders might be interested in this free visualization of analyst forecasts.Has PTC Therapeutics, Inc. Been A Good Investment?Boasting a total shareholder return of 232% over three years, PTC Therapeutics, Inc. has done well by shareholders. So they may not be at all concerned if the CEO were to be paid more than is normal for companies around the same size.In Summary...Stuart Peltz is paid around what is normal the leaders of comparable size companies.The company isn't showing particularly great growth, but shareholder returns have been pleasing. So considering most shareholders would be happy, we'd say the CEO pay is appropriate. So you may want to check if insiders are buying Therapeutics shares with their own money (free access).Important note: Therapeutics may not be the best stock to buy. You might find something better in this list of interesting companies with high ROE and low debt. If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoAsian markets continue to slump, as Nikkei enters correction territoryMarketWatch'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoPublic Storage only bidder left for National Storage with $1.25 billion bidReutersStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchThis company is revamping presentation softwareYahoo Finance VideoBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo Finance